The Oncologist: Several updates from the phase II BYLieve trial also examined outcomes across patient subgroups—in this case, patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer who progressed on or after prior treatment with a cyclin dependent kinase (CDK) 4/6 inhibitor. The gene discussed is ERBB2; the disease is breast carcinoma.